Cardax has reported that its lead compound Heptax has shown potential to address metabolic syndrome, including liver and cardiovascular disease as well as diabetes.
Heptax is a bioavailable proprietary derivative of the natural dietary carotenoid astaxanthin that addresses metabolic syndrome.
Preclinical animal studies with the company’s compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels.
The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the liver and the vasculature.
David Watumull, CEO of Cardax, said: We believe this to be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome.